GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LTR Pharma Ltd (ASX:LTP) » Definitions » ROE % Adjusted to Book Value

LTR Pharma (ASX:LTP) ROE % Adjusted to Book Value : -6.06% (As of Dec. 2024)


View and export this data going back to 2023. Start your Free Trial

What is LTR Pharma ROE % Adjusted to Book Value?

LTR Pharma's ROE % for the quarter that ended in Dec. 2024 was -25.83%. LTR Pharma's PB Ratio for the quarter that ended in Dec. 2024 was 4.26. LTR Pharma's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 was -6.06%.

LTR Pharma ROE % Adjusted to Book Value Historical Data

The historical data trend for LTR Pharma's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LTR Pharma ROE % Adjusted to Book Value Chart

LTR Pharma Annual Data
Trend Jun21 Jun22 Jun23 Jun24
ROE % Adjusted to Book Value
- - - -3.59

LTR Pharma Semi-Annual Data
Jun21 Jun22 Jun23 Dec23 Jun24 Dec24
ROE % Adjusted to Book Value Get a 7-Day Free Trial - - -9.61 -5.16 -6.06

Competitive Comparison of LTR Pharma's ROE % Adjusted to Book Value

For the Biotechnology subindustry, LTR Pharma's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

LTR Pharma's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, LTR Pharma's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where LTR Pharma's ROE % Adjusted to Book Value falls into.


;
;

LTR Pharma ROE % Adjusted to Book Value Calculation

LTR Pharma's ROE % Adjusted to Book Value for the fiscal year that ended in Jun. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-133.36% / 37.14
=-3.59%

LTR Pharma's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-25.83% / 4.26
=-6.06%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LTR Pharma ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of LTR Pharma's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

LTR Pharma Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LTR Pharma Ltd (ASX:LTP) » Definitions » ROE % Adjusted to Book Value
Comparable Companies
ASX:AGN ASX:ACW ASX:RCE ASX:EZZ ASX:PIQ ASX:NUZ ASX:ATH ASX:RAD ASX:TYP ASX:SPL VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY ONC BNTX XKRX:068270
Traded in Other Exchanges
N/A
Address
9A/204 Alice Street, Brisbane, QLD, AUS, 4000
Website
https://www.ltrpharma.com
LTR Pharma Ltd is a clinical stage pharmaceutical company focused on holistically improving men's health, physically and mentally, through the commercialization of an intranasal spray treatment for Erectile Dysfunction. SPONTAN is a Vardenafil-based nasal delivery formulation designed to be a lower dose fast-acting administration that provides a rapid and high availability to a patient's bloodstream compared with the incumbent oral ED treatment products on the market.

LTR Pharma Headlines

No Headlines